The Effect of Pioglitazone on the Liver

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Diabetes Care

• Publication date

  2006-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/dc05-2445PMID 17003306
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes.

  2006cited by this paper
• Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats

  2005cited by this paper
• A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

  2005cited by this paper
• Effects of Angiotensin Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease: The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial: The PEACE Study Investigators

  2005cited by this paper
• Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.

  2004cited by this paper
• Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach.

  2004cited by this paper
• Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes.

  2004influential reference
• Splanchnic lipolysis in human obesity.

  2004cited by this paper
• Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients

  2004cited by this paper
• A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.

  2004cited by this paper
• Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.

  2004cited by this paper
• Complex Distribution, Not Absolute Amount of Adiponectin, Correlates with Thiazolidinedione-mediated Improvement in Insulin Sensitivity*

  2004cited by this paper
• Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes.

  2003cited by this paper
• Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.

  2003cited by this paper
• Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet

  2003cited by this paper
• Effect of thiazolidinediones on body weight in patients with diabetes mellitus.

  2003cited by this paper
• Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.

  2002cited by this paper
• Metabolic effects of visceral fat accumulation in type 2 diabetes.

  2002cited by this paper
• Small increases in insulin inhibit hepatic glucose production solely caused by an effect on glycogen metabolism.

  2001cited by this paper
• Endogenous glucose production is inhibited by the adipose-derived protein Acrp30.

  2001cited by this paper
• Comprehensive Messenger Ribonucleic Acid Profiling Reveals That Peroxisome Proliferator-Activated Receptor γ Activation Has Coordinate Effects on Gene Expression in Multiple Insulin-Sensitive Tissues.

  2001cited by this paper
• Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.

  2001cited by this paper
• Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

  2001cited by this paper
• Central Role of the Adipocyte in the Metabolic Syndrome

  2001cited by this paper
• Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPARgamma mRNA expression in 3T3-L1 adipocytes.

  2001cited by this paper
• Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues.

  2001influential reference
• Determination of the enrichment of the hydrogen bound to carbon 5 of glucose on 2H2O administration.

  2001cited by this paper
• Effect of physiological hyperinsulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients.

  2001cited by this paper
• Determinants of postabsorptive endogenous glucose output in non-diabetic subjects

  2000cited by this paper
• A Dominant-negative Peroxisome Proliferator-activated Receptor γ (PPARγ) Mutant Is a Constitutive Repressor and Inhibits PPARγ-mediated Adipogenesis*

  2000cited by this paper
• Role of glucose and insulin in thiazolidinedione-induced alterations in hepatic gluconeogenesis.

  2000cited by this paper
• Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells.

  2000cited by this paper
• A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis.

  2000cited by this paper
• Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study.

  2000cited by this paper
• Peroxisome proliferator-activated receptors: nuclear control of metabolism.

  1999cited by this paper
• Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus

  1999cited by this paper
• Comparative effects of englitazone and glyburide on gluconeogenesis and glycolysis in the isolated perfused rat liver.

  1998cited by this paper
• PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.

  1998cited by this paper
• Effect of troglitazone (Rezulin) on fructose 2,6-bisphosphate concentration and glucose metabolism in isolated rat hepatocytes.

  1998cited by this paper
• Basal hepatic glucose production is regulated by the portal vein insulin concentration.

  1998cited by this paper
• Identification of High-Affinity Binding Sites for the Insulin Sensitizer Rosiglitazone (BRL-49653) in Rodent and Human Adipocytes Using a Radioiodinated Ligand for Peroxisomal Proliferator-Activated Receptor γ

  1998cited by this paper
• Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma.

  1998cited by this paper
• Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids.

  1997cited by this paper
• Acute effects of pioglitazone on glucose metabolism in perfused rat liver

  1997cited by this paper
• Pioglitazone Induces In Vivo Adipocyte Differentiation in the Obese Zucker fa/fa Rat

  1997cited by this paper
• Assay of the deuterium enrichment of water via acetylene.

  1996cited by this paper
• Use of Gas Chromatography/Ion‐trap Tandem Mass Spectrometry for the Determination of Chemical Markers of Microorganisms in Organic Dust

  1996cited by this paper
• Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.

  1996cited by this paper
• Contributions of gluconeogenesis to glucose production in the fasted state.

  1996cited by this paper
• Total Body Fat Content and Fat Topography Are Associated Differently With In Vivo Glucose Metabolism in Nonobese and Obese Nondiabetic Women

  1992cited by this paper
• Measurement of abdominal fat with T1‐weighted MR images

  1991cited by this paper
• Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance.

  1989cited by this paper
• Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake.

  1989cited by this paper

• Factors Affecting the Treatment Heterogeneity of PPARγ and Pan-PPAR Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Machine Learning-Based Meta-Regression Analysis

  2026cites this paper
• Optimizing Measures of Insulin-Regulated Lipolysis in Humans.

  2025cites this paper
• Metabolic effects and mechanism of action of the pan PPAR agonist Lanifibranor.

  2025cites this paper
• Decades old glitazones still find niche in drug discoveries as PPAR-γ agonists: medicinal chemistry perspective, structure-activity relationships and therapeutic implications.

  2025cites this paper
• Exploring the potential of drug repurposing for liver diseases: A comprehensive study.

  2024cites this paper
• The Role of Organokines in Obesity and Type 2 Diabetes and Their Functions as Molecular Transducers of Nutrition and Exercise

  2023cites this paper
• The effect of thiazolidinediones on body fat redistribution in adults: A systematic review and meta‐analysis of randomized controlled trials

  2023cites this paper
• Measuring and estimating insulin resistance in clinical and research settings

  2022cites this paper
• Targeting the liver in dementia and cognitive impairment: Dietary macronutrients and diabetic therapeutics

  2022cites this paper
• Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes

  2022cites this paper
• Walnut Meal Extracts Rich In Polyphenols Mitigate Insulin Resistance and Modulate Gut Microbiota in High Fat Diet-Fed Rats

  2022cites this paper
• A global view of the interplay between non-alcoholic fatty liver disease and diabetes.

  2022cites this paper
• PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients

  2022cites this paper
• Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models

  2022cites this paper
• Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)

  2022cites this paper
• Walnut Meal Extracts Rich in Polyphenols Mitigate Insulin Resistance and Modulate the Gut Microbiota of High Fat Diet-fed Rats

  2021cites this paper
• Liver-targeting drugs and their effect on blood glucose and hepatic lipids

  2021cites this paper
• PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH

  2021cites this paper
• Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial.

  2021cites this paper
• PPARs as Metabolic Sensors and Therapeutic Targets in Liver Diseases

  2021cites this paper
• Insulin sensitivity depends on the route of glucose administration

  2020cites this paper
• A role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the treatment of Alzheimer's disease?

  2020cites this paper
• Participation of white adipose tissue dysfunction on circulating HDL cholesterol and HDL particle size in apparently healthy humans

  2019cites this paper
• Individuals With Prediabetes Display Different Age-Related Pathophysiological Characteristics.

  2019cites this paper
• Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes

  2019cites this paper
• Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis.

  2018influential citation
• Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.

  2017cites this paper
• Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes

  2017cites this paper
• Targeting Sirt1 in a rat model of high-fat diet-induced non-alcoholic fatty liver disease: Comparison of Gegen Qinlian decoction and resveratrol

  2017cites this paper
• Favorable cardiovascular effects of pioglitazone: a meta-analysis

  2017cites this paper
• PGC-1 alfa como regulador inflamatório na esteato-hepatite não-alcoólica

  2016cites this paper
• Mechanisms by which the thiazolidinedione troglitazone protects against sucrose‐induced hepatic fat accumulation and hyperinsulinaemia

  2016cites this paper
• Identification of subgroups with differential treatment effects for longitudinal and multiresponse variables

  2016cites this paper
• Revitalization of pioglitazone: the optimum agent to be combined with a sodium‐glucose co‐transporter‐2 inhibitor

  2016cites this paper
• The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo

  2015cites this paper
• PPAR gamma gene--a review.

  2015cites this paper
• Early Clinical Detection of Pharmacologic Response in Insulin Action in a Nondiabetic Insulin-Resistant Population

  2015cites this paper
• Intervening TNF-α via PPARγ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease

  2015cites this paper
• Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.

  2015cites this paper
• Pioglitazone Increases Whole Body Insulin Sensitivity in Obese, Insulin-Resistant Rhesus Monkeys

  2015cites this paper
• Combination therapy in type 2 diabetes mellitus

  2015cites this paper
• Pioglitazone: lessons and learnings 15 years since launch and beyond

  2015cites this paper
• Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention

  2015cites this paper
• Regulation of glucose and lipid homeostasis by adiponectin: effects on hepatocytes, pancreatic β cells and adipocytes.

  2014cites this paper
• Current challenges to overcome in the management of type 2 diabetes mellitus and associated neurological disorders.

  2014cites this paper
• Expansion of the Homeostasis Model Assessment of β-Cell Function and Insulin Resistance to Enable Clinical Trial Outcome Modeling Through the Interactive Adjustment of Physiology and Treatment Effects: iHOMA2

  2013cites this paper
• Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes

  2013cites this paper
• In Vivo Actions of Peroxisome Proliferator–Activated Receptors

  2013cites this paper
• Ectopic fat: the true culprit linking obesity and cardiovascular disease?

  2013cites this paper
• Pleiotropic Effects of Thiazolidinediones: Implications for the Treatment of Patients With Type 2 Diabetes Mellitus

  2013cites this paper
• Markers in nonalcoholic steatohepatitis.

  2013cites this paper
• ApproachtoTherap y in Patients With Newly Diagnosed Type 2 Diabetes

  2013cites this paper
• Personalized Management of Hyperglycemia in Type 2 Diabetes

  2013cites this paper
• Thiazolidinediones improve hepatic fibrosis in rats with non‐alcoholic steatohepatitis by activating the adenosine monophosphate‐activated protein kinase signalling pathway

  2012influential citation
• The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact.

  2011cites this paper
• Aerobic exercise improves insulin resistance and decreases body fat and serum levels of leptin in patients with hepatitis C virus

  2011cites this paper
• Inflammation in nonalcoholic steatohepatitis

  2011cites this paper
• Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009

  2010cites this paper
• Fat mass largely contributes to insulin mediated glucose uptake in morbidly obese subjects

  2010cites this paper
• Pioglitazone in the treatment of NASH: the role of adiponectin

  2010cites this paper
• Constituents from Cistus salvifolius (Cistaceae) Activate Peroxisome Proliferator-Activated Receptor-γ but Not -δ and Stimulate Glucose Uptake by Adipocytes

  2010cites this paper
• Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going.

  2010cites this paper
• ORIGINAL ARTICLE: Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican‐American patients with Type 2 diabetes: a double tracer OGTT study

  2010cites this paper
• złowieszczego oktetu ” : nowy model leczenia cukrzycy typu 2 From the triumvirate to the „ ominous octet ” : a new paradigm for the treatment of type 2 diabetes mellitus

  2009cites this paper
• The effect of pioglitazone on the liver of streptozotocin-induced diabetic albino Wistar rats.

  2009cites this paper
• Imaging and laboratory biomarkers in cardiovascular disease.

  2009cites this paper
• A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy.

  2009cites this paper
• From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

  2009cites this paper
• Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis

  2009cites this paper
• UvA-DARE ( Digital Academic Repository ) Adiponectin in glucose metabolism

  2008cites this paper
• Plasma C5 Glucose–to–2H2O Ratio Does Not Provide an Accurate Assessment of Gluconeogenesis During Hyperinsulinemic-Euglycemic Clamps in Either Nondiabetic or Diabetic Humans

  2008cites this paper
• Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis.

  2008cites this paper
• Pioglitazone Decreases Fasting and Postprandial Endogenous Glucose Production in Proportion to Decrease in Hepatic Triglyceride Content

  2008cites this paper
• Comparison of the Effects of Pioglitazone and Metformin on Hepatic and Extra-Hepatic Insulin Action in People With Type 2 Diabetes

  2008cites this paper
• PPAR-gamma-independent inhibitory effect of rosiglitazone on glucose synthesis in primary cultured rabbit kidney-cortex tubules.

  2008cites this paper
• patient-oriented and epidemiological research A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes

  2008cites this paper
• Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes

  2008cites this paper
• Pioglitazone and cardiovascular risk. A comprehensive meta‐analysis of randomized clinical trials

  2008cites this paper
• Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin‐sensitizing agents

  2008cites this paper
• Short Insulin Tolerance Test Can Determine the Effects of Thiazolidinediones Treatment in Type 2 Diabetes

  2008cites this paper
• A rosiglitazone-induced increase in plasma adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy 8

  2008influential citation
• Adiponectin in glucose metabolism

  2008cites this paper
• Pharmacokinetic/Pharmacodynamic Modelling in Diabetes Mellitus

  2008cites this paper
• Insulin resistance as the underlying cause for the metabolic syndrome.

  2007cites this paper
• Thiazolidinediones improve -cell function in type 2 diabetic patients

  2007cites this paper
• Thiazolidinediones improve beta-cell function in type 2 diabetic patients.

  2007cites this paper
• Vascular Health and Risk Management Dovepress Pioglitazone and Alogliptin Combination Therapy in Type 2 Diabetes: a Pathophysiologically Sound Treatment

  year unknowncites this paper